Boggs, Anna E.
Schmitt, Lauren M.
McLane, Richard D.
Adayev, Tatyana
LaFauci, Giuseppe
Horn, Paul S.
Dominick, Kelli C.
Gross, Christina
Erickson, Craig A.
Funding for this research was provided by:
National Institutes of Health (U54HD104461)
Article History
Received: 10 September 2021
Accepted: 17 February 2022
First Online: 4 April 2022
Competing interests
: The authors have no financial interests specifically related to the content of this manuscript. CAE is a current consultant to Confluence, Stalicla, Impel, Forge, and Scioto Bioscience. CAE is the inventor on patents related to the treatment of autism and/or Fragile X Syndrome.